What Is MOTS-c? Benefits, Research & Safety
A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.
UK summary: Not a licensed UK medicine. Mitochondrial-derived peptide studied largely in preclinical animal and cell models. Sold by some online retailers as 'research only'. Likely captured by WADA's S0 non-approved substances category.
Quick Facts
Overview
MOTS-c — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Mitochondrial-derived peptide studied largely in preclinical animal and cell models. Sold by some online retailers as 'research only'. Likely captured by WADA's S0 non-approved substances category.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: MOTS-c is an early-stage research compound. Human clinical trials are in planning stages. Not available through legitimate medical channels.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses biological ageing at the mitochondrial level.
- Acts as a complete substitute for cardio exercise.
- Boosts metabolism and burns visceral fat without diet change.
- Restores insulin sensitivity in type 2 diabetes.
07Common internet claims
- Exercise in a vial — the mitochondrial peptide bodybuilders take.
- Marketed as an anti-ageing breakthrough by longevity influencers.
- Sold as research-only with dosing protocols copied from rodent studies.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Reverses biological ageing” | E | No | High | Preclinical models show effects on mitochondrial metabolism; ageing-reversal claims in humans are not supported. |
| “Mimics the effects of exercise” | D | Limited | Moderate | Animal evidence suggests overlap with some exercise-related signalling; this does not equal substituting for exercise in humans. |
| “Boosts metabolism and burns fat” | D | No | High | Preclinical metabolic effects; human weight-loss claims are not established. |
| “Safe research peptide for personal use” | E | No | High | Long-term human safety is not established. 'Research only' labelling does not address UK regulatory questions about human-use marketing. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Injection site reactions reported anecdotally.
- Unknown systemic effects from sustained AMPK activation in humans.
- Theoretical interaction with metformin and other AMPK-modulating drugs.
- Long-term consequences of exogenous mitochondrial peptide signalling are unstudied in people.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- What dose of any online MOTS-c product is safe in humans — there is no licensed reference.
- Whether grey-market vials actually contain the labelled peptide.
- How chronic AMPK activation affects cancer risk, muscle wasting, or insulin signalling long-term.
- Whether it stacks safely with metformin, GLP-1 agonists, or berberine.
16Last reviewed
17Citation quality score
18Research gaps
- No published Phase 2 or Phase 3 human trials with hard outcomes.
- Pharmacokinetic data in humans is sparse.
- Dose-response relationships for any human endpoint are unestablished.
- Long-term safety entirely unknown.
19Safer alternatives / established care pathways
- Structured aerobic exercise — the actual stimulus MOTS-c is claimed to mimic.
- GP review for metformin if metabolic syndrome or pre-diabetes is the concern.
- Licensed weight-management referral if obesity is the target outcome.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is MOTS-c a licensed UK medicine?
- What does the human evidence look like outside of preclinical mitochondrial research?
- If I'm an athlete, what is the anti-doping position?
- What licensed treatments exist for the metabolic outcomes I'm asking about?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved insulin sensitivity in animal models
- 2Prevention of diet-induced obesity in mice
- 3Enhanced glucose metabolism and uptake
- 4Activation of AMPK and metabolic regulation
- 5Exercise mimetic effects on metabolism
- 6Potential role in healthy ageing
- 7Improved mitochondrial function
Claim vs Evidence
How popular claims about MOTS-c stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Reverses biological ageing” | E | No | High | Preclinical models show effects on mitochondrial metabolism; ageing-reversal claims in humans are not supported. |
| “Mimics the effects of exercise” | D | Limited | Moderate | Animal evidence suggests overlap with some exercise-related signalling; this does not equal substituting for exercise in humans. |
| “Boosts metabolism and burns fat” | D | No | High | Preclinical metabolic effects; human weight-loss claims are not established. |
| “Safe research peptide for personal use” | E | No | High | Long-term human safety is not established. 'Research only' labelling does not address UK regulatory questions about human-use marketing. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Not established; animal studies use various weight-based doses |
| Frequency | Variable in research settings |
| Duration | Not established for human use |
| Notes | MOTS-c is in early research stages without established human protocols. Any information on dosing should be considered highly experimental. Human clinical trials are needed to determine appropriate use. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (in animal research)
- Intraperitoneal injection (animal models)
| Half-Life | Stability |
|---|---|
| Limited human pharmacokinetic data available | Peptide stability data from research settings |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Limited safety data in humans
- Animal studies suggest generally well-tolerated
Rare Risks & Concerns
- Unknown long-term effects
- Effects on cancer cells uncertain
- Metabolic effects in diabetics could require medication adjustment
Contraindications
- Diabetes (potential blood glucose effects)
- Pregnancy and breastfeeding
- Active malignancy (effects unknown)
- Children and adolescents
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
MOTS-c: A Mitochondrial-Derived Peptide Regulating Metabolic Homeostasis
Discovery paper demonstrating MOTS-c's role in metabolic regulation and prevention of obesity and insulin resistance in mice.
Mitochondrial-Derived Peptides: Implication in the Therapy of Neurodegenerative Diseases.
Ethical Approval: Not applicable. Informed Consent: Not applicable.
MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment.
The key role of MOTS-c in the major diabetes-related complications is specifically explored, with a special focus on its protective and therapeutic potential in diabetic cardiomyopathy.
Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities.
We also provide insights into the current advancements in clinical research related to the utilization of MDPs in the treatment of CVDs. This review may provide valuable information with MDPs for CVD diagnosis and treatment.
Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.
MDPs attenuate disease pathology including Type 1 diabetes (T1D), Type 2 diabetes (T2D), gestational diabetes, Alzheimer's disease (AD), cardiovascular diseases, prostate cancer, and macular degeneration. The current review will focus on the MDP regulation of T2D, T1D, and gestational diabetes along with an emphasis on the evolutionary pressures for conservation of the amino acid sequences of MDPs.
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.
Throughout this paper, we discussed the discovery and physiological function of mitochondrial-derived polypeptide MOTS-c, and the application of MOTS-c in the treatment of various diseases, such as aging, cardiovascular disease, insulin resistance, and inflammation.
Registered Trials & Regulatory Status
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation
Status: Recruiting · 68 participants · University of Gaziantep
Conditions: Kidney Disease, End-Stage, Kidney Transplant, Kidney
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Status: Recruiting · 120 participants · Hudson Biotech
Conditions: Prediabetes, Insulin Resistance, Overweight/Obesity
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Status: Unknown · 120 participants · University of Athens
Conditions: Diabetes, Clopidogrel Resistance, Amyloid
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for MOTS-c?
Source research-grade MOTS-c from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about MOTS-c
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is MOTS-c a licensed UK medicine?
- What does the human evidence look like outside of preclinical mitochondrial research?
- If I'm an athlete, what is the anti-doping position?
- What licensed treatments exist for the metabolic outcomes I'm asking about?
UK regulatory & safety context
Related Research Guides
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreEpitalon
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Learn moreHumanin
A mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties, researched for neuroprotection, metabolic regulation, and ageing.
Learn more